# Juan W. Valle

Source: https://onco.cc/people/juan-valle/  
OnCo record `juan-valle` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led ABC-02, which made gemcitabine plus cisplatin the global standard for biliary cancer, and co-led TOPAZ-1.

## Summary

Juan Valle was chief investigator of ABC-02, the UK trial that established gemcitabine plus cisplatin as first-line therapy for advanced biliary tract cancer, and a lead investigator of TOPAZ-1, which added durvalumab to that backbone. He has led the ABC series of biliary trials and international guidelines on cholangiocarcinoma. He now leads research strategy at the Cholangiocarcinoma Foundation.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: biliary; chemotherapy; trialist
- Role: Chief Medical Officer, Cholangiocarcinoma Foundation; Honorary Professor of Medical Oncology, University of Manchester and The Christie
- Specialisms: Biliary tract cancer; Cholangiocarcinoma; Chemotherapy and immunotherapy; Rare GI cancers

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Valle%20JW%5BAuthor%5D%20biliary

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/)
- institutions: [The Christie NHS Foundation Trust](https://onco.cc/institutions/the-christie/)
- trials: [ABC-02](https://onco.cc/trials/abc-02/), [ABC-06](https://onco.cc/trials/abc-06/), [TOPAZ-1](https://onco.cc/trials/topaz-1/)
- key papers: [Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023/), [British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma](https://onco.cc/key-papers/paper-bsg-cholangiocarcinoma-guideline-gut-2023/), [Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study](https://onco.cc/key-papers/paper-topaz-1-three-year-survival-j-hepatol-2025/), [HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?](https://onco.cc/key-papers/paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017/), [Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial](https://onco.cc/key-papers/paper-abc-06-folfox-second-line-lancet-oncol-2021/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/juan-valle.json